Loading...

ATOS ATOSSA THERAPEUTICS INC Management Changes 8-K Filing

TSS

TS

ATOSSA THERAPEUTICS INC

(ATOS)

2025 8-K

FDA Meeting Update

Financial Update

Management Change

Corporate Presentation Update

New Regulatory Strategy

Nasdaq Compliance Update

Financial Statements

Patent Challenge

Financial Results

New Treatment Plans

Nasdaq Compliance

Patent Decision

Trial Data Presentation

Stock Sale Agreement

Financial Results

Positive Study Results

Financial Results

Annual Meeting and Manageme...

Earnings Report

Financial Results Announcement

Appointment of Director

Earnings Reports

Appointment of Director

Resignation and Appointment

Earnings Reports

Stock Repurchase Program

Appointment of Chief Financ...

Dismissal and Appointment o...

Financial Results Announcement

Annual Meeting Results

Bylaws Amendment

Earnings Report

External Links:

Atossa Therapeutics, Inc. appointed Mr. Mark Daniel as Chief Financial Officer and principal accounting officer on October 14, 2025, succeeding Ms. Heather Rees, who will assist in the transition until November 15, 2025.

AI Assistant

ATOSSA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.